Presentation Description: Osteosarcoma was initially considered to be a chemo-resistant tumor. In the early 1970s high dose Methotrexate and amputation administered alone or in combination with other agents yielded a cure rate of 40-65 percent. This result was challenged. In this presentation, the saga of the controversy and the final acceptance of the regimen is described.
Speaker:
Norman Jaffe, MD, Dip Paed, DSc
Professor Emeritus
The University of Texas MD Anderson Cancer Centre, Houston, TX